Brief: Nasdaq Panel Grants Transcode Therapeutics Extension For Continued Listing
27/10/2023 13:11
Oct 27 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* NASDAQ PANEL GRANTS TRANSCODE THERAPEUTICS EXTENSION FOR
CONTINUED LISTING ON THE NASDAQ STOCK MARKET SUBJECT TO
CONDITIONS
Source text for Eikon: ID:nGNX67gF7Q
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors